Your session is about to expire
← Back to Search
Anti-metabolites
Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or Esophageal Adenocarcinoma
Phase 1 & 2
Waitlist Available
Led By Jaffer A. Ajani, MD
Research Sponsored by Mebiopharm Co., Ltd
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
All Individual Drugs Already Approved
Approved for 5 Other Conditions
No Placebo-Only Group
Summary
This trial is testing MBP-426, a new medication, in patients whose stomach or esophagus cancer did not respond to initial treatments. The study aims to find the best dose that works well and has fewer side effects.
Eligible Conditions
- Stomach Cancer
- Gastroesophageal Junction Adenocarcinoma
- Esophageal Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Study of MBP-426/leucovorin/5-FUExperimental Treatment1 Intervention
Study of MBP-426/leucovorin/5-FU. MBP-426 will be administered at a dose of 170 mg/m2 every three weeks. Leucovorin will be administered ata dose of 400 mg/m2 after the MBP-426 infusion and in the absence of allergy/infusion reaction. 5-FU is administered concurrently with the leucovorin infusion and after the MBP-426 administration as a 46-hour continuous infusion of 2400 mg/m2.
Find a Location
Who is running the clinical trial?
Mebiopharm Co., LtdLead Sponsor
1 Previous Clinical Trials
39 Total Patients Enrolled
Jaffer A. Ajani, MDPrincipal InvestigatorUT MD Anderson Cancer Center
6 Previous Clinical Trials
2,869 Total Patients Enrolled